Innate Pharma presents proprietary antibody-drug conjugate technology at the World ADC Summit in San Francisco

• New site-specific conjugation technology for homogenous antibody-drug conjugates (ADCs)
• Provides further opportunities for portfolio expansion and partnering

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces that its new, site-specific conjugation technology will be presented today at the World ADC Summit, taking place in San Francisco, CA, October 14-17, 2013.

A detailed presentation will be given by Florence Lhospice, Director, Pharmaceutical Operations, at 3:00–3.30pm local time: “Towards Homogenous ADCs: A New Site-Specific Conjugation based on Bacterial Transglutaminase”.

Hervé Brailly, CEO of Innate Pharma, said: “Antibody drug conjugates are a very promising and validated class of antibody drugs that can potentially be combined with immunomodulating antibodies. Innate Pharma’s proprietary technology presented today addresses a bottleneck in ADCs development: rapidly obtaining homogenous ADCs based on a minimal change of the manufacturing process. It is a versatile approach that may be used for a broad spectrum of target antigens and which can accommodate both existing and future high potency toxins. This technical achievement creates new opportunities for portfolio expansion and partnering”.